[HTML][HTML] Matrix metalloproteinases regulate neovascularization by acting as pericellular fibrinolysins

N Hiraoka, E Allen, IJ Apel, MR Gyetko, SJ Weiss - Cell, 1998 - cell.com
During angiogenesis, endothelial cells penetrate fibrin barriers via undefined proteolytic
mechanisms. We demonstrate that the fibrinolytic plasminogen activator (PA)-plasminogen …

[HTML][HTML] Targeting SWI/SNF ATPases in enhancer-addicted prostate cancer

…, SA Simko, AD Delekta, M Jaber, H Zheng, IJ Apel… - Nature, 2022 - nature.com
The switch/sucrose non-fermentable (SWI/SNF) complex has a crucial role in chromatin
remodelling 1 and is altered in over 20% of cancers 2 , 3 . Here we developed a proteolysis-…

Targeting transcriptional regulation of SARS-CoV-2 entry factors ACE2 and TMPRSS2

…, JCY Tien, X Cao, SA Simko, IJ Apel… - Proceedings of the …, 2021 - National Acad Sciences
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), the virus responsible for
COVID-19, employs two key host proteins to gain entry and replicate within cells, angiotensin-…

BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonists in the treatment of prostate cancer

…, PM Krishnamurthy, IJ Apel, J Escara-Wilke… - Molecular Cancer …, 2016 - AACR
Next-generation antiandrogen therapies, such as enzalutamide and abiraterone, have had
a profound impact on the management of metastatic castration-resistant prostate cancer (…

Cleavage of NIK by the API2-MALT1 fusion oncoprotein leads to noncanonical NF-κB activation

S Rosebeck, L Madden, X Jin, S Gu, IJ Apel, A Appert… - science, 2011 - science.org
Proper regulation of nuclear factor κB (NF-κB) transcriptional activity is required for normal
lymphocyte function, and deregulated NF-κB signaling can facilitate lymphomagenesis. We …

[HTML][HTML] Androgen receptor degraders overcome common resistance mechanisms developed during prostate cancer treatment

…, P Bawa, BL McCollum, K Wilder-Romans, IJ Apel… - Neoplasia, 2020 - Elsevier
Androgen receptor (AR) antagonists, such as enzalutamide, have had a major impact on the
treatment of metastatic castration-resistant prostate cancer (CRPC). However, even with the …

[PDF][PDF] Development of peptidomimetic inhibitors of the ERG gene fusion product in prostate cancer

…, BVSK Chakravarthi, X Cao, X Jing, CX Wang, IJ Apel… - Cancer cell, 2017 - cell.com
Transcription factors play a key role in the development of diverse cancers, and therapeutically
targeting them has remained a challenge. In prostate cancer, the gene encoding the …

c-myc and bcl-2 modulate p53 function by altering p53 subcellular trafficking during the cell cycle.

…, E Prochownik, CA Gottlieb, IJ Apel… - Proceedings of the …, 1994 - National Acad Sciences
We have studied the ability of c-myc and bcl-2 oncogenes to modulate p53 function. Our
studies show that coincident expression of human Bcl-2 protein with p53 prolongs survival of …

Discovery of a highly potent and selective dual PROTAC degrader of CDK12 and CDK13

…, Y Zhou, P Zhang, W Huang, J Vo, IJ Apel… - Journal of Medicinal …, 2022 - ACS Publications
Selective degradation of the cyclin-dependent kinases 12 and 13 (CDK12/13) presents a
novel therapeutic opportunity for triple-negative breast cancer (TNBC), but there is still a lack of …

[HTML][HTML] Multiple phosphorylated isoforms of NRL are expressed in rod photoreceptors

PK Swain, D Hicks, AJ Mears, IJ Apel, JE Smith… - Journal of Biological …, 2001 - ASBMB
NRL, a bZIP transcription factor of the Maf subfamily, interacts with the homeodomain protein
CRX and synergistically regulates rhodopsin expression. Here we report that six isoforms …